TY - JOUR
T1 - Diabetes and pancreatic cancer survival
T2 - A prospective cohort-based study
AU - Toriola, A. T.
AU - Stolzenberg-Solomon, R.
AU - Dalidowitz, L.
AU - Linehan, D.
AU - Colditz, G.
N1 - Funding Information:
Adetunji T Toriola is supported by the Washington University School of Medicine, Barnes-Jewish Hospital Foundation, and Siteman Cancer Center.
PY - 2014/7
Y1 - 2014/7
N2 - Background:Diabetes is a risk factor for pancreatic cancer but its association with survival from pancreatic cancer is poorly understood. Our objective was to investigate the association of diabetes with survival among pancreatic cancer patients in a prospective cohort-based study where diabetes history was ascertained before pancreatic cancer diagnosis.Methods:We evaluated survival by baseline (1993-2001) self-reported diabetes history (n=62) among 504 participants that developed exocrine pancreatic cancer within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality were estimated using Cox proportional hazards model, adjusted for age, sex, body mass index, race, smoking, and tumour stage (local, locally advanced, and metastatic).Results:The multivariable-adjusted HR for mortality comparing participants with diabetes to those without was 1.52 (95% CI=1.14-2.04, P-value <0.01). After excluding those diagnosed with pancreatic cancer within 3 years of study enrolment, HR for mortality among those with diabetes was 1.45 (95% CI=1.06-2.00, P-value=0.02).Conclusions:Using prospectively collected data, our findings indicate that diabetes is associated with worse survival among patients with pancreatic cancer.
AB - Background:Diabetes is a risk factor for pancreatic cancer but its association with survival from pancreatic cancer is poorly understood. Our objective was to investigate the association of diabetes with survival among pancreatic cancer patients in a prospective cohort-based study where diabetes history was ascertained before pancreatic cancer diagnosis.Methods:We evaluated survival by baseline (1993-2001) self-reported diabetes history (n=62) among 504 participants that developed exocrine pancreatic cancer within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality were estimated using Cox proportional hazards model, adjusted for age, sex, body mass index, race, smoking, and tumour stage (local, locally advanced, and metastatic).Results:The multivariable-adjusted HR for mortality comparing participants with diabetes to those without was 1.52 (95% CI=1.14-2.04, P-value <0.01). After excluding those diagnosed with pancreatic cancer within 3 years of study enrolment, HR for mortality among those with diabetes was 1.45 (95% CI=1.06-2.00, P-value=0.02).Conclusions:Using prospectively collected data, our findings indicate that diabetes is associated with worse survival among patients with pancreatic cancer.
KW - cohort
KW - diabetes
KW - mortality
KW - pancreatic cancer
KW - prospective study
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=84904117457&partnerID=8YFLogxK
U2 - 10.1038/bjc.2014.224
DO - 10.1038/bjc.2014.224
M3 - Article
C2 - 24786605
AN - SCOPUS:84904117457
VL - 111
SP - 181
EP - 185
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 1
ER -